15
Jul
2021
Payers Revolt Against Biogen’s Aduhelm, FDA Credibility Crisis, and a Prime Financing
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Jul
2021
Verge Genomics Strikes Deal with Lilly to Validate New Targets for ALS
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Jul
2021
Biogen’s Perilous Path, Intellia’s In Vivo Milestone, & Holiday Financings
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jun
2021
Lander Pushes ARPA-H, Lilly Follows Fast in Alzheimer’s, & Wyden Moderates on Price
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jun
2021
EQRx, Exscientia Team Up to Accelerate R&D for Lower-Priced, Better Drugs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Jun
2021
Novavax Nails Vaccine Trial, CureVac Fails, & Flagship Sails on With $3.4B
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Jun
2021
On Juneteenth, Honoring 22 Black Biotech Leaders
A few Black people have risen to prominence in biopharma. Ken Frazier, Tony Coles, Rob Perez and Ted Love are among the most visible. But there are many other Black leaders in the industry who are making important contributions to the science and business of human health. Today, let’s recognize the Juneteenth holiday coming up June 19. It’s a celebration... Read More
15
Jun
2021
Mentoring Young Scientists: Jay Bradner and Andy Plump on The Long Run
This episode of The Long Run is a little different. I invited a couple previous guests on The Long Run to discuss a specific issue: How the industry can do a better job of mentoring young scientists, and creating on-ramps to careers in the biopharma industry for people from underrepresented groups. Jay Bradner, the president of the Novartis Institutes for... Read More
14
Jun
2021
Biotech Pride: 19 Industry Leaders Who Identify as LGBTQ
Scientists have created mRNA vaccines that are saving millions of lives. Better cancer drugs are in the works. Gene editing technologies, and gene therapies, offer potential cures. Teams of dedicated people are making these things happen, and many of the people on these teams identify as LGBTQ. As part of Pride Month, I asked TR readers to nominate members of... Read More
10
Jun
2021
Biogen’s Alzheimer’s Controversy, Cytokine Startups Reload, and Vaccines Beat Variants
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Jun
2021
Amgen’s KRAS Triumph, Eric Lander in the Saddle, and EQRx Takes Aim at PD-L1
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Jun
2021
Spatial Biology Coming Into Focus: Brad Gray on The Long Run
Today’s guest on The Long Run is Brad Gray. Brad is the CEO of Seattle-based NanoString Technologies. NanoString started out in the early 2000s by making digital “bar codes” that allowed it to do multi-plex gene expression – the analysis of multiple genes at once, and the extent to which they were dialled on or off in a given sample.... Read More
27
May
2021
GSK, Vir Win Antibody OK, Sanofi-GSK Moves to Phase III, & a Day One IPO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
May
2021
GSK Persists with Vaccines, ASCO Abstracts, & Biogen Gene Therapy Fizzles
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
May
2021
Pfizer Advances to Adolescents, Xontogeny’s New Fund & Rekindling Curiosity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
May
2021
Biden Threatens Patents, Vaccines Shine, & Biogen’s Pricing Predicament
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
May
2021
Startup Profiles: Perlmutter Bets on Super Microscopy; Foresite’s Precision Immunology
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
May
2021
Spotting Trends and Starting Edgy Companies: Daphne Zohar on The Long Run
Today’s guest on The Long Run is Daphne Zohar. Daphne is the founder and CEO of Boston-based Puretech Health. Puretech has been around since 2005, seeking to capitalize on some of the big trends in biotech. It started out seeking to test concepts from academic labs that could be the basis for new biotech companies – what’s now commonly called... Read More
29
Apr
2021
J&J Back After Pause, Sanofi Aids Moderna, and a Flood of Women Join Biotech Boards
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Apr
2021
Versant Ventures, Sticking With its Knitting, Raises $950M for Early Stage Biotechs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.